Bioneex Company Profile

Background

Mission and Vision

Bioneex is dedicated to accelerating biopharmaceutical partnerships and investment deals by connecting innovative drug development companies with the right partners and investors at the right time.

Primary Area of Focus

Bioneex operates as the first R&D open exchange platform in the biopharmaceutical industry, facilitating licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies, and research institutions.

Industry Significance

By providing a secure online marketplace, Bioneex enables direct connections between drug developers and potential partners or investors, streamlining the process of bringing novel therapies to market.

Key Strategic Focus

Core Objectives

• Enhance the efficiency of biopharmaceutical R&D collaborations.

• Provide a centralized platform for drug candidate listings.

• Facilitate direct communication between biotech firms and investors.

Areas of Specialization

• Preclinical and clinical-stage drug candidate partnerships.

• Licensing and co-development agreements.

• Investment facilitation in the biopharmaceutical sector.

Key Technologies Utilized

• AI-driven matchmaking algorithms to connect stakeholders.

• Secure data-sharing protocols for sensitive information.

Primary Markets Targeted

• Biotech and biopharma companies seeking partnerships.

• Venture capital firms interested in biopharmaceutical investments.

• Research institutions with drug candidates for development.

Financials and Funding

Funding History

• Seed Round (February 2024): Raised $0.5 million, led by former executives from Pfizer and Amgen.

• Ongoing Funding Round (2024): Initiated a $6 million funding round to further expand platform capabilities.

Notable Investors

• Business Angel Network of Armenia.

• ALSA Ventures.

Utilization of Capital

• Enhancing user experience on the Bioneex platform.

• Improving client support services.

• Developing new services for a global client base.

Pipeline Development

As a platform provider, Bioneex does not develop its own drug candidates but facilitates the development pipelines of its users by connecting them with appropriate partners and investors.

Technological Platform and Innovation

Proprietary Technologies

• AI-powered marketplace for drug candidates, utilizing advanced algorithms to match potential partners and facilitate pharmaceutical innovations.

Significant Scientific Methods

• Implementation of machine learning algorithms to enhance matchmaking accuracy between biotech firms and investors.

Leadership Team

• Dr. Smbat Rafayelyan – Founder & CEO

• Edgar Marukyan – Chief Technology Officer

• Katerina Epimakhova – Director of Portfolio Development

• Jose Franco Álvarez, PhD – Scientific Manager

• Narine Manukyan – Marketing and Investor Relations Manager

• Marie Daghlian – Chief Editor

• Tigran Rafayelyan – Project Manager

• Armen Andreasyan – Scientific Associate

• Emin Avagyan – Platform Engineer

• Reto Galstyan – Frontend Developer

Advisory Board

• Dr. Andreas Penk – Former President of Pfizer China

• Scott Dorfman – Venture Partner at Fulcrum Equity Partners

• Sebouh Nahabedian – Managing Director at Francisco Partners

• Dr. Graeme Martin – Former CEO of Takeda Ventures

• Ben Williams – Co-Founder & CBO at 4M Therapeutics

• Dan Zavodnick – Managing Partner at NorthStar Advisors

• Ray Jordan – Former Corporate Affairs Officer at Amgen, J&J, and Moderna

• Dr. Alfred Scheidegger – Founder & Board Member of Nextech Invest

Leadership Changes

• October 2022: Dr. Andreas Penk, former President of Pfizer China, joined the Bioneex Advisory Board to support expansion into the global oncology space and addition of Chinese biopharma innovation to its exchange platform.

Competitor Profile

Market Insights and Dynamics

The biopharmaceutical R&D business development platform market is characterized by a growing demand for efficient matchmaking between drug developers and potential partners or investors. The integration of AI and machine learning technologies is becoming increasingly prevalent to enhance the accuracy and efficiency of these connections.

Competitor Analysis

• Yseop: An AI software company that transforms data into written insights in real-time.

• deepsense.ai: Provides AI-powered software solutions across various industries.

• KUBRA: Offers customer experience management solutions, including AI-driven services.

• Sinops: Develops automatic ordering systems and AI solutions for various sectors.